The PREVENT-AD cohort: accelerating Alzheimer′s disease research and treatment in Canada and beyond

  1. Sylvia Villeneuve
  2. Judes Poirier
  3. John C.S. Breitner
  4. Jennifer Tremblay-Mercier
  5. Jordana Remz
  6. Jean-Michel Raoult
  7. Yara Yakoub
  8. Jonathan Gallego Rudolf
  9. Ting Qiu
  10. Alfonso Fajardo Valdez
  11. Bery Mohammediyan
  12. Mohammadali Javanray
  13. Amelie Metz
  14. Safa Sanami
  15. Valentin Ourry
  16. Alfie Wearn
  17. Alexandre Pastor Bernier
  18. Manon Edde
  19. Julie Gonneaud
  20. Cherie Strikwerda-Brown
  21. Christine L Tardif
  22. Claudine J Gauthier
  23. Maxime Descoteaux
  24. Mahsa Dadar
  25. Etienne Vachon-Presseau
  26. Andree-Ann Baril
  27. Simon Ducharme
  28. Maxime Montembeault
  29. Maiya R. Geddes
  30. Jean-Paul Soucy
  31. Natasha Rajah
  32. Robert Laforce
  33. Christian Bocti
  34. Christos Davatzikos
  35. Lune Bellec
  36. Pedro Rosa-Neto
  37. Sylvain Baillet
  38. Alan C Evans
  39. D Louis Collins
  40. M Mallar Chakravarty
  41. Kaj Blennow
  42. Henrik Zetterberg
  43. R Nathan Spreng
  44. Alexa Pichet Binette
  45. PREVENT-AD Research Group
0 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

The PREVENT-AD is an investigator-driven study that was created in 2011 and enrolled cognitively normal older adults with a family history of sporadic AD. Participants are deeply phenotyped and have now been followed annually for more than 12 years [median follow-up 8.0 years, SD 3.1]. Multimodal MRI, genetic, neurosensory, clinical, cerebrospinal fluid and cognitive data collected until 2017 on 348 participants who agreed to open sharing with the neuroscience community were already available. We now share a new release including 6 years of additional follow-up cognitive data, and additional MRI follow-ups, clinical progression, new longitudinal behavioral and lifestyle measures (questionnaires, actigraphy), longitudinal AD plasma biomarkers, amyloid-beta and tau PET, magnetoencephalography, as well as neuroimaging analytic measures from all MRI modalities. We describe the PREVENT-AD study, the data shared with the global research community as well as the model we created to sustain longitudinal follow-ups while also allowing new innovative data collection.

Related articles

Related articles are currently not available for this article.